Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

December 28, 2023

https://www.globenewswire.com/news-release/2023/12/27/2801370/0/en/Bluejay-Diagnostics-Inc-Announces-Initiation-of-Multicenter-Clinical-Study-Evaluating-Symphony-IL-6-in-Sepsis-Patients-SYMON-Study.html

This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives.

ACTON, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ:BJDX) (“Bluejay” or the “Company”), today announced the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients (the SYMON study). The Symphony System is designed to address the need for simple, reliable, rapid, near-patient testing by providing quantitative measurements of specific biomarkers to determine the need for additional patient care and monitoring. The Symphony System was shown in published clinical studies to deliver results directly from whole blood in approximately 20 minutes.

Read more at globenewswire.com

Related news for (BJDX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.